Aptose Biosciences Analyst Ratings
Aptose Biosciences Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/07/2023 | 887.01% | Cantor Fitzgerald | → $38 | Reiterates | Overweight → Overweight |
| 08/11/2023 | 211.69% | Piper Sandler | $37 → $12 | Maintains | Overweight |
| 08/11/2023 | 497.4% | RBC Capital | $40 → $23 | Maintains | Outperform |
| 08/11/2023 | 497.4% | HC Wainwright & Co. | $12 → $23 | Maintains | Buy |
| 08/11/2023 | 289.61% | Oppenheimer | $50 → $15 | Maintains | Outperform |
| 06/12/2023 | 497.4% | HC Wainwright & Co. | $12 → $23 | Maintains | Buy |
| 06/12/2023 | 887.01% | Cantor Fitzgerald | $6 → $38 | Maintains | Overweight |
| 06/12/2023 | 1198.7% | Oppenheimer | $9 → $50 | Maintains | Outperform |
| 06/07/2023 | 861.04% | Piper Sandler | $45 → $37 | Maintains | Overweight |
| 06/07/2023 | 938.96% | RBC Capital | $75 → $40 | Maintains | Outperform |
| 05/09/2023 | 133.77% | Oppenheimer | → $9 | Reiterates | → Outperform |
| 05/09/2023 | 29.87% | RBC Capital | → $5 | Reiterates | → Outperform |
| 05/09/2023 | 211.69% | HC Wainwright & Co. | → $12 | Reiterates | → Buy |
| 03/27/2023 | 107.79% | Canaccord Genuity | $13 → $8 | Maintains | Buy |
| 03/24/2023 | 29.87% | RBC Capital | → $5 | Reiterates | → Outperform |
| 11/02/2022 | 29.87% | RBC Capital | $6 → $5 | Maintains | Outperform |
| 05/10/2022 | 55.84% | RBC Capital | $7 → $6 | Maintains | Outperform |
| 12/21/2021 | 211.69% | HC Wainwright & Co. | $14 → $12 | Maintains | Buy |
| 11/12/2021 | 263.64% | HC Wainwright & Co. | $9 → $14 | Maintains | Buy |
| 03/24/2021 | 133.77% | Oppenheimer | $8 → $9 | Maintains | Outperform |
| 02/20/2020 | 315.58% | Maxim Group | → $16 | Initiates Coverage On | → Buy |
| 01/09/2020 | 159.74% | Piper Sandler | → $10 | Initiates Coverage On | → Overweight |
| 08/07/2019 | 55.84% | HC Wainwright & Co. | $8.5 → $6 | Reiterates | → Buy |
| 01/25/2019 | 55.84% | Oppenheimer | → $6 | Initiates Coverage On | → Outperform |
| 11/16/2018 | 29.87% | B. Riley Securities | → $5 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 09/07/2023 | 887.01% | 康託·菲茨傑拉德 | →$38 | 重申 | 超重→超重 |
| 2023年08月11日 | 211.69% | 派珀·桑德勒 | $37→$12 | 維護 | 超重 |
| 2023年08月11日 | 497.4% | 加拿大皇家銀行資本 | $40→$23 | 維護 | 跑贏大盤 |
| 2023年08月11日 | 497.4% | HC Wainwright公司 | $12→$23 | 維護 | 買 |
| 2023年08月11日 | 289.61% | 奧本海默 | $50→$15 | 維護 | 跑贏大盤 |
| 2023/06/12 | 497.4% | HC Wainwright公司 | $12→$23 | 維護 | 買 |
| 2023/06/12 | 887.01% | 康託·菲茨傑拉德 | $6→$38 | 維護 | 超重 |
| 2023/06/12 | 1198.7% | 奧本海默 | $9→$50 | 維護 | 跑贏大盤 |
| 06/07/2023 | 861.04% | 派珀·桑德勒 | $45→$37 | 維護 | 超重 |
| 06/07/2023 | 938.96% | 加拿大皇家銀行資本 | $75→$40 | 維護 | 跑贏大盤 |
| 05/09/2023 | 133.77% | 奧本海默 | →$9 | 重申 | →跑贏大盤 |
| 05/09/2023 | 29.87% | 加拿大皇家銀行資本 | →$5 | 重申 | →跑贏大盤 |
| 05/09/2023 | 211.69% | HC Wainwright公司 | →$12 | 重申 | →購買 |
| 03/27/2023 | 107.79% | 卡納科特·格納奇 | $13→$8 | 維護 | 買 |
| 03/24/2023 | 29.87% | 加拿大皇家銀行資本 | →$5 | 重申 | →跑贏大盤 |
| 11/02/2022 | 29.87% | 加拿大皇家銀行資本 | $6→$5 | 維護 | 跑贏大盤 |
| 2022年05月10日 | 55.84% | 加拿大皇家銀行資本 | $7→$6 | 維護 | 跑贏大盤 |
| 2021/12/21 | 211.69% | HC Wainwright公司 | $14→$12 | 維護 | 買 |
| 2021年11月12日 | 263.64% | HC Wainwright公司 | $9→$14 | 維護 | 買 |
| 03/24/2021 | 133.77% | 奧本海默 | $8→$9 | 維護 | 跑贏大盤 |
| 02/20/2020 | 315.58% | Maxim集團 | →$16 | 開始承保 | →購買 |
| 1/09/2020 | 159.74% | 派珀·桑德勒 | →$10 | 開始承保 | →超重 |
| 2019年08月07日 | 55.84% | HC Wainwright公司 | $8.5→$6 | 重申 | →購買 |
| 2019年01月25日 | 55.84% | 奧本海默 | →$6 | 開始承保 | →跑贏大盤 |
| 2018年11月16日 | 29.87% | B.萊利證券 | →$5 | 開始承保 | →購買 |
What is the target price for Aptose Biosciences (APTO)?
Aptose Biosciences(APTO)的目標價格是多少？
The latest price target for Aptose Biosciences (NASDAQ: APTO) was reported by Cantor Fitzgerald on September 7, 2023. The analyst firm set a price target for $38.00 expecting APTO to rise to within 12 months (a possible 887.01% upside). 16 analyst firms have reported ratings in the last year.
康託·菲茨傑拉德於2023年9月7日報道了Aptose Biosciences(納斯達克：APTO)的最新目標價。這家分析公司將目標價定為38美元，預計APTO將在12個月內升至(可能上漲887.01%)。過去一年，有16家分析公司公佈了評級。
What is the most recent analyst rating for Aptose Biosciences (APTO)?
Aptose Biosciences(APTO)的最新分析師評級是多少？
The latest analyst rating for Aptose Biosciences (NASDAQ: APTO) was provided by Cantor Fitzgerald, and Aptose Biosciences reiterated their overweight rating.
納斯達克(Sequoia Capital：APTO)的最新分析師評級由康託·菲茨傑拉德提供，Aptose Biosciences重申其增持評級。
When is the next analyst rating going to be posted or updated for Aptose Biosciences (APTO)?
Aptose Biosciences(APTO)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aptose Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aptose Biosciences was filed on September 7, 2023 so you should expect the next rating to be made available sometime around September 7, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Aptose Biosciences的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Aptose Bioscience的上一次評級是在2023年9月7日提交的，所以你應該預計下一次評級將在2024年9月7日左右的某個時候提供。
Is the Analyst Rating Aptose Biosciences (APTO) correct?
分析師對Aptose Biosciences(APTO)的評級正確嗎？
While ratings are subjective and will change, the latest Aptose Biosciences (APTO) rating was a reiterated with a price target of $0.00 to $38.00. The current price Aptose Biosciences (APTO) is trading at is $3.85, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Aptose Biosciences(APTO)評級被重申，目標價在0.00美元至38.00美元之間。Aptose Biosciences(APTO)目前的交易價格為3.85美元，在分析師的預測範圍內。